VacChina 2011—Vaccine Development Summit (Nov 29-30, Shanghai)

VacChina 2011—Vaccine Development Summit

Nov 29 to Nov 30, 2011 Shanghai, China

Up to now, China has become third largest vaccine market in the world with annual sales turnover over USD 1 billion. With China’s government attaching more importance to the disease control and prevention, public health and vaccine R&D, China’s vaccine market has emerged again as a hotbed for global big pharma and biotech for their future growth.

In 2009 the Chinese Government announced an infusion of US$ 124 billion into the healthcare sector to improve insurance cover, infrastructure and access to vaccination nationwide. The government is not only subsidizing a wider range of vaccines, but it is also racing to invest in its own R&D. Under 12 Five Year plan, The National Development and Reform Commission made novel vaccine development a priority and the China’s vaccine market size will continue growing to RMB50 billion. With the help of modern proteomics and genomics technologies, the development of novel vaccine in China is marching toward combined vaccines, new adjuvant, multivalent vaccines, and therapeutic vaccines.

To address tomorrow’s vaccine development in China, VacChina 2011-China’s No.1 vaccine summit features a unique line up of speakers from the global to discuss China opportunities under current global vaccine market landscape and introduce experiences from India’s and MNC pharma on strategies for technology transfer, investment, internationalization, market entry, modern vaccine technologies with the aim to build a partnering platform for vaccine development in China. For industry stakeholders, VacChina 2011-Vaccine Development Summit will provide an excellent opportunity for those companies looking to have their presence in the Asian emerging market especially in China or establish initial contact with the Asian vaccine manufacturers.

Key Issues VacChina 2011—Vaccine Development Summit：

•   vaccine R&D models
•   emerging market investment opportunities
•   market access strategies
•   technology transfer and licensing
•   12 Five Years’ plan factor
•   therapeutic and novel vaccine technologies
•   clinical trial design and outsourcing

•   modern adjuvant production and characterization
•   next generation influenza vaccines
•   capacity building for vaccine manufacturing
•   single use technologies
•   cell culture evolutions
•   emerging facilities design
•   operation excellence & new cGMP

Speakers:

Xinliang Shen

Vice President; China National Biotec Group

Andrew T. Natenshon
Head China Strategy & Operations; Novartis Vaccines & Diagnostics

Joseph D Santangelo

COO; Inviragen (Singapore) Pte. Ltd.

BG Rhee Bio

a President and CEO of Expression Genetics, Inc. ;Green Cross Corp

Haifa Zheng

General Manager;Beijing Minhai Biotechnology Co., Ltd.

Chen Ze
Professor and Assistant Director; Shanghai Institute of Biological Products, Shanghai, China

Bin Wang
a professor; Fudan University Shanghai Medical College

 

Who should attend?

Who will be there?

•   Pharma companies
•   Vaccine companies 
•    Biotech companies
•   Vaccine delivery technologies
•   Vaccine adjuvant
•   Manufacturing equipments
•   Law firms and consultants
•   Cell culture
•   Bioprocess technology
•   Facility design
•   Contract research organizations
•   Clinical research organizations
•   Distributors
•   Distribution, logistic and warehousing
•   Packaging and fill
•   Venture capitalists
•   Others

Who will benefit?

From Pharmaceutical companies, vaccine manufacturers, biotech companies, research institutes, Academia

With job titles Chief Executives, Scientific Officers and Senior Director/Director
who manage following business units:

•   Business Development / Strategic Alliances
•   Research and Development
•   Clinical Development
•   Regulatory Affairs
•   Strategic Product Development
•   Manufacturing/Production Technology
•   Pharmacovigilance and Safety Testing
•   Supply Outsourcing
•   Project Management
•   Others

For more information, please contact Daniel Chen by +86 21 32516046 or Email to

daniel.chen@globaleaders.com

 

Website: http://vac.globaleaders.com/